Home » Stocks » Vivus, Inc

Vivus, Inc. (VVUS)

Jul 17, 2020 - VVUS was delisted due to bankruptcy and now trades as VVUSQ
Stock Price: $0.467 USD -0.054 (-10.29%)
Updated Jul 16, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 8.34M
Revenue (ttm) 73.25M
Net Income (ttm) -28.77M
Shares Out 17.87M
EPS (ttm) -2.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $0.467
Previous Close $0.520
Change ($) -0.054
Change (%) -10.29%
Day's Open -
Day's Range 0.460 - 0.500
Day's Volume 0
52-Week Range 0.437 - 4.750

More Stats

Market Cap 8.34M
Enterprise Value 217.35M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.87M
Float 16.62M
EPS (basic) -2.70
EPS (diluted) -2.70
FCF / Share -2.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.01M
Short Ratio 3.45
Short % of Float 18.09%
Beta -0.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.11
PB Ratio n/a
Revenue 73.25M
Operating Income -8.92M
Net Income -28.77M
Free Cash Flow -23.44M
Net Cash -209.02M
Net Cash / Share -11.70
Gross Margin 59.84%
Operating Margin -12.18%
Profit Margin -39.30%
FCF Margin -32.00%
ROA -2.20%
ROE n/a
ROIC -8.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$1.75*
Low
1.75
Current: $0.467
High
1.75
Target: 1.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue69.7665.0665.3712495.4311481.082.01--
Revenue Growth7.22%-0.48%-47.39%30.21%-16.42%40.82%3929.92%---
Gross Profit54.0950.4548.7311461.2780.7976.211.83--
Operating Income-10.97-3.482.7955.69-60.28-50.71-155-140-47.08-65.63
Net Income-31.50-36.95-30.5123.30-93.11-82.65-174-140-46.14-66.07
Shares Outstanding10.6410.6210.5710.4410.3910.3510.129.838.448.10
Earnings Per Share-2.96-3.48-2.892.22-9.00-8.00-17.20-14.20-5.50-8.20
Operating Cash Flow-30.47-23.61-16.3638.17-46.33-38.11-135-132-36.90-64.11
Capital Expenditures-0.04-0.03-0.02-0.21-0.31-0.26-1.80-1.67-0.20-0.11
Free Cash Flow-30.52-23.64-16.3937.95-46.64-38.37-137-134-37.10-64.21
Cash & Equivalents32.65111226270242300343215147139
Total Debt243294236241231228213---
Net Cash / Debt-210-183-9.3528.2010.1771.79130215147139
Assets218302265306277367432264152144
Liabilities28834227428828428427841.2110.9712.28
Book Value-69.22-40.02-9.3418.19-7.0982.52153223141132
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vivus, Inc.
Country United States
Employees 59
CEO John P. Amos

Stock Information

Ticker Symbol VVUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VVUS
IPO Date April 6, 1994

Description

VIVUS operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.